30.17
3.33%
-1.04
Corcept Therapeutics Inc stock is currently priced at $30.17, with a 24-hour trading volume of 1.34M.
It has seen a -3.33% decreased in the last 24 hours and a +29.37% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $31.32 pivot point. If it approaches the $30.07 support level, significant changes may occur.
Previous Close:
$31.21
Open:
$31.39
24h Volume:
1.34M
Market Cap:
$3.14B
Revenue:
$523.53M
Net Income/Loss:
$118.02M
P/E Ratio:
37.25
EPS:
0.81
Net Cash Flow:
$124.84M
1W Performance:
+9.63%
1M Performance:
+29.37%
6M Performance:
+18.45%
1Y Performance:
+28.44%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650-327-3270
Address
149 Commonwealth Drive, Menlo Park
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-06-23 | Upgrade | Truist | Hold → Buy |
Apr-11-23 | Initiated | SVB Securities | Market Perform |
Apr-04-23 | Initiated | Piper Sandler | Overweight |
Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
Aug-01-22 | Downgrade | Truist | Buy → Hold |
Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
Jun-27-22 | Resumed | Canaccord Genuity | Buy |
Feb-02-22 | Initiated | Canaccord Genuity | Buy |
Jan-28-22 | Initiated | Truist | Buy |
Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
Sep-24-19 | Initiated | Jefferies | Buy |
Sep-06-19 | Initiated | H.C. Wainwright | Buy |
Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
Aug-10-18 | Reiterated | Stifel | Hold |
May-31-18 | Downgrade | Stifel | Buy → Hold |
Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
Aug-31-17 | Initiated | Stifel | Buy |
Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
Apr-21-15 | Initiated | FBR Capital | Outperform |
Jan-13-14 | Downgrade | Stifel | Buy → Hold |
Aug-09-13 | Downgrade | Janney | Buy → Neutral |
Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Gary Charles Robb Sells 11000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock - Defense World
Defense World
Q1 2025 Earnings Forecast for Corcept Therapeutics Incorporated (NASDAQ:CORT) Issued By Zacks Research - MarketBeat
MarketBeat
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue? - Yahoo Canada Finance
Yahoo Canada Finance
Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ... By GuruFocus - Investing.com Canada
Investing.com Canada
Corcept Therapeutics exec sells over $330k in stock - Investing.com India
Investing.com India
Corcept Therapeutics exec sells over $330k in stock - Investing.com South Africa
Investing.com South Africa
Corcept Therapeutics Inc Stock (CORT) Financials Data
Corcept Therapeutics Inc (CORT) Revenue 2024
CORT reported a revenue (TTM) of $523.53 million for the quarter ending March 31, 2024, a +26.51% rise year-over-year.
Corcept Therapeutics Inc (CORT) Net Income 2024
CORT net income (TTM) was $118.02 million for the quarter ending March 31, 2024, a +24.89% increase year-over-year.
Corcept Therapeutics Inc (CORT) Cash Flow 2024
CORT recorded a free cash flow (TTM) of $124.84 million for the quarter ending March 31, 2024, a +12.84% increase year-over-year.
Corcept Therapeutics Inc (CORT) Earnings per Share 2024
CORT earnings per share (TTM) was $1.06 for the quarter ending March 31, 2024, a +29.27% growth year-over-year.
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Cap:
|
Volume (24h):